Catherine Creticos is an Infectious Disease physician affiliated with Howard Brown Health Center. OpenAlex indexes 29 publications with 1,145 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingIndustry payments
36 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
36 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
47.3%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor12.4%Isentress36%Tivicay30%Isentress Hd19%Dovato15%Part D<11 patientsProtease Inhibitor11.5%Prezcobix59%Symtuza26%Ritonavir15%Part D<11 patients+ 6 more classes in this area
Nervous system
22.8%Gabapentinoids7.5%Gabapentin100%Part D<11 patientsSSRI4.2%Trazodone Hcl61%Fluoxetine Hcl39%Part D<11 patients+ 4 more classes in this area
Cardiovascular
9.5%Statin5.2%Atorvastatin Calcium63%Rosuvastatin Calcium37%Part D<11 patientsCalcium channel blocker2.3%Amlodipine Besylate100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Subcutaneous Lenacapavir in People With Multidrug-Resistant HIV-1: 156 Week Results of the CAPELLA Study
Open Forum Infectious Diseases
2025 - 155. Long-Acting Subcutaneous Lenacapavir in People with Multi-Drug Resistant HIV-1: 3-Year Results of the CAPELLA Study
Open Forum Infectious Diseases
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Thomas Walsh, MD
Cornell University
Vance Fowler, MD
Duke University
Derrick W. Crook
Nuffield Orthopaedic Centre
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”